The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study
Authors:
- Taweegrit SiripongboonsittiTSTaweegrit Siripongboonsitti
- Kriangkrai TawinpraiKTKriangkrai Tawinprai
- Kunsuda CheirsilpaKCKunsuda Cheirsilpa
- Teerapat UngtrakulTUTeerapat Ungtrakul
- Wasanai KrisorakunWKWasanai Krisorakun
- Chanisa ChotipanichCCChanisa Chotipanich
- Nat WimolsiriNWNat Wimolsiri
- Permpen NoitunPNPermpen Noitun
- Netnapis SrirattanaNSNetnapis Srirattana
- Nithi MahanondaNMNithi Mahanonda
Open Access
Abstract
Background: Favipiravir has complex pharmacokinetics, and varied efficacy has been reported in treating COVID-19. Telehealth and telemonitoring are disruptive challenges used for COVID-19 care during pandemics. Objective: This study aimed to assess the outcome of favipiravir treatment to prevent clinical deterioration in mild to moderate COVID-19 cases with adjunctive telemonitoring during the COVID-19 surge. Methods: This was a retrospective observational study of PCR-confirmed mild to moderate COVID-19 cases subjected to home isolation. Chest computed tomography (CT) was performed in all cases, and favipiravir was administrated. Results: This study involved 88 PCR-confirmed COVID-19 cases. In addition, 42/42 (100%) cases were Alpha variants. COVID-19 pneumonia was found in 71.5% of the cases, according to chest X-rays and chest CT on the first visit. Favipiravir started 4 days after symptoms, which was part of the standard of care. The 12.5% of the patients required supplemental oxygen and intensive care unit admission rate was 1.1%; 1.1% required mechanical ventilation, and the rate of all-cause mortality was 1.1%, with a value of 0% of severe COVID-19 deaths. All mild illness cases showed no clinical deterioration or requirement for supplemental oxygen. No significant deterioration in either obesity or diabetes mellitus was observed. Conclusions: Favipiravir treatment for mild to moderate COVID-19 cases in outpatient settings, coupled with telemonitoring, was both safe and effective in preventing clinical deterioration, including the need for oxygen supplementation. This approach proved valuable during surges of COVID-19 cases.Keywords
Funding Information
- Chulabhorn Royal Academy, Bangkok, Thailand (no.E2566/056)
This publication has 52 references indexed in Scilit:
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control StudyEngineering, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Telehealth for global emergencies: Implications for coronavirus disease 2019 (COVID-19)Journal of Telemedicine and Telecare, 2020
- Favipiravir versus Arbidol for COVID-19: A Randomized Clinical TrialmedRxiv, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymeraseProceedings of the Japan Academy, Series B, 2017
- Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy TrialsClinical Pharmacokinetics, 2016